Group items tagged

With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-​effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC&'s current research priorities: Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. Developing testing protocols to detect designer substances used for doping purposes. Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. Developing analytical methods to detect performance enhancing drugs not currently detectable. Longitudinal urinary excretion patterns, metabolism and dose-concentration. Critical reviews to support interpretation of laboratory data. Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing. APPLY FOR A GRANT Sign up for our newsletter

The PCC has supported world-class research since 2009, spending more than $8.0 M to support novel science. Research and grant-making are the foundation of the PCC and are the focus of everyday business activity. PCC-supported research contributes to a movement in addressing doping's root causes and ultimately decreasing the use of performance-enhancing drugs by all participants in all sports at all levels of play. With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: - Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. - Developing testing protocols to detect designer substances used for doping purposes. - Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. - Developing analytical methods to detect performance enhancing drugs not currently detectable. - Longitudinal urinary excretion patterns, metabolism and dose-concentration. - Critical reviews to support interpretation of laboratory data. - Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.

With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: - Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. - Developing testing protocols to detect designer substances used for doping purposes. - Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. - Developing analytical methods to detect performance enhancing drugs not currently detectable. - Longitudinal urinary excretion patterns, metabolism and dose-concentration. - Critical reviews to support interpretation of laboratory data. - Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.

The PCC has supported world-class research since 2008, spending more than $18.0 M to support novel science around the world. Research and grant-making are the foundation of the PCC and are the focus of everyday business activity. PCC-supported research contributes to a movement in addressing doping's root causes and ultimately decreasing the use of performance-enhancing drugs by all participants in all sports at all levels of play. Grant Cycle Deadlines: Pre-Applications are due March 1st, July 1st, and November 1st of each year. Applicants invited to submit full applications must do so by April 1st, August 1st, or December 1st, depending on the cycle (30 days after the pre-application due date). With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. Developing testing protocols to detect designer substances used for doping purposes. Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. Developing analytical methods to detect performance enhancing drugs not currently detectable. Longitudinal urinary excretion patterns, metabolism and dose-concentration. Critical reviews to support interpretation of laboratory data. Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing. There is no maximum amount for PCC funding, though the average funding amount is $225,000. To date, over 80 projects have been funded in over 14 countries world-wide. Approximately 33% of applicants are awarded PCC funding.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes the ability to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. FOA Emphasis. The FOA utilizes the R33 mechanism which is suitable for projects where proof-of-principle of the proposed technology or methodology has been demonstrated and supportive preliminary data are available. Proposed projects should offer new tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The emphasis of this FOA is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, screening, clinical diagnosis, treatment, epidemiology, or address issues in cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

he NIDCR-funded FaceBase Consortium (www.facebase.org) was established in 2009 to advance craniofacial research by creating comprehensive datasets on craniofacial development and dysmorphologies and disseminating them to the wider craniofacial research community. Operationally, the Consortium links individual spoke projects, each creating and contributing comprehensive datasets, analytic tools, and other resources to a central data management and integration hub which, in turn, disseminates them publicly. This Funding Opportunity Announcement (FOA) solicits grant applications for a new round of spoke projects that will comprise the Consortiums second iteration. New projects should be consistent with FaceBases overall goals of experimental data collection and annotation, data coordination, and integration. New projects should also be complementary to, rather than duplicative of, the types of data, analytic tools, and resources already available through FaceBase. The Consortium will continue to focus on normal craniofacial development and dysmorphology but this FOA is open to applications investigating parts of the skull beyond the midface and palate. High programmatic priority will be given to studies of facial, palatal, and cranial vault development and dysmorphology.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), the Division of Epidemiology, Statistics, and Prevention Research intends to solicit proposals to award an Indefinite Delivery Indefinite Quantity (IDIQ) contract to an organization to conduct various studies focusing on a spectrum of health effects in men, women, and children that rely on quantification of analytes in biological specimens such as blood, urine, adipose tissue, follicular fluids, and seminal fluids.  The Division needs a variety of banked specimens analyzed for concentrations of various hormone levels, dietary biomarkers, and indicators of metabolic function among other analytes.

This FOA encourages Research Conference Grant (R13) applications from institutions and organizations that propose to develop interdisciplinary research teams. Teams must include investigators from the social and/or behavioral sciences, and may include the life and/or physical sciences.  The goal is to broaden the scope of investigation into scientific problems, yield fresh and possibly unexpected insights, and increase the sophistication of theoretical, methodological, and analytical approaches by integrating the analytical strengths of two or more disparate scientific disciplines while addressing gaps in terminology, approach, and methodology.  This program will allow investigators from multiple disciplines to hold meetings in order to provide the foundation for developing interdisciplinary research projects.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing technically innovative feasibility studies focused on early-stage development of technologies that address issues related to pre-analytical variations in the collection, processing, handling, and storage of cancer-relevant biospecimens or their derivatives. The overall goal is to develop technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or samples derived from those biospecimens for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to potentially accelerate and/or enhance research in cancer biology, early detection, screening, clinical diagnosis, treatment, epidemiology, and cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. All projects must include quantitative milestones (i.e., technical metrics that determine whether the specific aims have been accomplished). This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

The Science of Science & Innovation Policy (SciSIP) program supports research designed to advance the scientific basis of science and innovation policy. Research funded by the program thus develops, improves and expands models, analytical tools, data and metrics that can be applied in the science policy decision making process. For example, research proposals may develop behavioral and analytical conceptualizations, frameworks or models that have applications across a broad array of SciSIP challenges, including the relationship between broader participation and innovation or creativity. Proposals may also develop methodologies to analyze science and technology data, and to convey the information to a variety of audiences. Researchers are also encouraged to create or improve science and engineering data, metrics and indicators reflecting current discovery, particularly proposals that demonstrate the viability of collecting and analyzing data on knowledge generation and innovation in organizations. Among the many research topics supported are:examinations of the ways in which the contexts, structures and processes of science and engineering research are affected by policy decision, the evaluation of the tangible and intangible returns from investments in science and from investments in research and development, the study of structures and processes that facilitate the development of usable knowledge, theories of creative processes and their transformation into social and economic outcomes, the collection, analysis and visualization of new data describing the scientific and engineering enterprise. The SciSIP program invites the participation of researchers from all of the social, behavioral and economic sciences as well as those working in domain-specific applications such as chemistry, biology, physics, or nanotechnology. The program welcomes proposals for individual or multi-investigator research projects, doctoral dissertation improvement awards, conferences, wo

The NIEHS is establishing an infrastructure, the Human Health Exposure Analysis Resource (HHEAR) as a continuation of the Children's Health Exposure Analysis Resource (CHEAR). The goal of this consortium is to provide the research community access to laboratory and statistical analyses to add or expand the inclusion of environmental exposures in their research and to make that data publicly available as a means to improve our knowledge of the comprehensive effects of environmental exposures on human health throughout the life course. This FOA solicits Laboratories (Lab Hubs) providing a comprehensive suite of analysis of environmental exposures in samples such as dust, soil, and drinking water related to the immediate environment of individuals and linked to health endpoints. Each Hub will incorporate a developmental core to develop novel measures for environmental samples, expanding the number of current, commonly measured analytes, and developing new methods for detecting analytes in other environmental samples and providing additional insight into the sources of exposures that influence human health. The Environmental Monitoring Lab will also serve as a 'clearinghouse for evaluation and provision of emerging tools and technologies for personal exposure assessment to the client community.

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials.  Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints. Although research supported by this FOA can include animal studies, it must also include preliminary human validation using carefully standardized human samples or human clinical studies. The goal of this initiative is to deliver candidate biomarkers, biomarker signatures, and/or endpoints that are ready for advanced clinical and analytical validation research.

GSK is seeking rapid, point of care analytical tests for gene therapy products that can go from sample to result within 2 hours   Tests should work with human cells at a concentration of 1x106 - 1x108 cells per mL in growth media. They should characterize / quantify the populations of cell immunophenotypes in the sample.   Lab tests are welcome. GSK would be especially interested in analytical techniques that could be carried out at or close to the patient's bedside.

CMMT supports theoretical and computational materials research in the topical areas represented in DMR's Topical Materials Research Programs (these are also variously known as Individual Investigator Award (IIA) Programs, or Core Programs, or Disciplinary Programs), which include: Condensed Matter Physics (CMP), Biomaterials (BMAT), Ceramics (CER), Electronic and Photonic Materials (EPM), Metals and Metallic Nanostructures (MMN), Polymers (POL), and Solid State and Materials Chemistry (SSMC). The CMMT program supports fundamental research that advances conceptual understanding of hard and soft materials, and materials-related phenomena; the development of associated analytical, computational, and data-centric techniques; and predictive materials-specific theory, simulation, and modeling for materials research.Research may encompass the advance of new paradigms in materials research, including emerging data-centric approaches utilizing data-analytics or machine learning. Computational efforts span from the level of workstations to advanced and high-performance scientific computing. Emphasis is on approaches that begin at the smallest appropriate length scale, such as electronic, atomic, molecular, nano-, micro-, and mesoscale, required to yield fundamental insight into material properties, processes, and behavior, to predict new materials and states of matter, and to reveal new materials phenomena. Approaches that span multiple scales of length and time may be required to advance fundamental understanding of materials properties and phenomena, particularly for polymeric materials and soft matter.

The purpose of this Funding Opportunity Announcement (FOA) is to develop advanced analytical models, tools and metrics to enhance the decision making and professional evaluation in life sciences management and administration. It is envisioned that the developed tools will be used by the NGOs/disease foundations, advocacy groups, publishing industry, research funders, policy makers and academic institutions.

 The purpose of this Funding Opportunity Announcement (FOA) is to develop advanced analytical models, tools and metrics to enhance the decision making and professional evaluation in life sciences management and administration. It is envisioned that the developed tools will be used by the NGOs/disease foundations, advocacy groups, publishing industry, research funders, policy makers and academic institutions.

This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies and blood biospecimens utilized as liquid biopsies. Extramural research funded under this FOA may include investigations of preanalytical variability relevant to diagnostic associated with the procurement and study of small biopsies (core biopsies, small excision samples), pleural aspirates, and blood utilized for liquid biopsies. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.